Wiśniewska-Chudy Ewa, Szylberg Łukasz, Dworacki Grzegorz, Mizera-Nyczak Ewa, Marszałek Andrzej
Department of Clinical Pathomorphology, Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, 85-092 Bydgoszcz, Poland.
Department of Clinical Immunology, Poznań University of Medical Sciences, 60-806 Poznań, Poland.
Oncol Rep. 2017 Apr;37(4):2295-2307. doi: 10.3892/or.2017.5476. Epub 2017 Feb 24.
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic progenitor cell disorders characterized by the proliferation of one or more hematopoietic lineages. The classical MPNs include polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) entities. These disorders are characterized by bone marrow morphology typical for each disease, and by the presence of JAK2V617F mutation in the marrow and blood. However, JAK2V617F cannot account for the phenotypic heterogeneity of MPNs because approximately half of all cases of ET and PMF show no evidence of this molecular marker. Therefore, the search for novel markers of these diseases is necessary to improve pathomorphological and molecular diagnostics. This study aimed to investigate the changes in expression patterns of the proteins STAT5 (the signal transducers and activators of transcription 5) and ERK (extracellular signal-regulated kinase) in bone marrow trephine specimens, derived both from patients with wild-type and mutant (V617F) forms of JAK2 kinase. Furthermore, the changes in STAT5 and ERK2 gene expression levels in the same patients were also investigated. The results of our immunohistochemical, immunoblotting and RT-qPCR studies revealed at least four major unique features of three types of MPNs. These include: i) more pronounced expression of phosphoSTAT5 protein in patients with JAK2V617F mutation compared to patients with wild-type of JAK2 kinase ii) different expression pattern of pSTAT5 in the nucleus and the cytoplasm of megakaryocytes and other bone marrow cells; iii) approximately 5-fold higher expression level of STAT5a gene in PV in comparison to patients with PMF and approximately 2-fold higher than in ET patients; iv) different, intracellular expression patterns of ERK2 and ERK1/2 antigens allowed to distinguish each subtype of MPN. These abnormalities in expression patterns of STAT5 and ERK proteins and genes provide some novel molecular features of MPNs and brings us closer to explaining the pathogenesis of MPNs.
骨髓增殖性肿瘤(MPNs)是一类克隆性造血祖细胞疾病,其特征为一种或多种造血谱系的增殖。经典的MPNs包括真性红细胞增多症(PV)、原发性血小板增多症(ET)和原发性骨髓纤维化(PMF)。这些疾病的特征在于每种疾病典型的骨髓形态,以及骨髓和血液中JAK2V617F突变的存在。然而,JAK2V617F不能解释MPNs的表型异质性,因为大约一半的ET和PMF病例没有这种分子标志物的证据。因此,寻找这些疾病的新标志物对于改善病理形态学和分子诊断是必要的。本研究旨在调查骨髓活检标本中信号转导和转录激活因子5(STAT5)及细胞外信号调节激酶(ERK)蛋白表达模式的变化,这些标本来自具有野生型和突变型(V617F)JAK2激酶的患者。此外,还研究了同一患者中STAT5和ERK2基因表达水平的变化。我们的免疫组织化学、免疫印迹和RT-qPCR研究结果揭示了三种类型MPNs至少四个主要的独特特征。这些特征包括:i)与具有野生型JAK2激酶的患者相比,JAK2V617F突变患者中磷酸化STAT5蛋白的表达更明显;ii)pSTAT5在巨核细胞和其他骨髓细胞核与细胞质中的表达模式不同;iii)与PMF患者相比,PV患者中STAT5a基因的表达水平高约5倍,比ET患者高约2倍;iv)ERK2和ERK1/2抗原不同的细胞内表达模式可区分MPNs的每个亚型。STAT5和ERK蛋白及基因表达模式的这些异常提供了MPNs的一些新分子特征,并使我们更接近解释MPNs的发病机制。